title: The proteinuria-hypertriglyceridemia connection as a basis for novel therapeutics for nephrotic syndrome.
abstract: The development of new and specific treatment options for kidney disease in general and glomerular diseases in specific has lagged behind other fields like heart disease and cancer. As a result, nephrologists have had to test and adapt therapeutics developed for other indications to treat glomerular diseases. One of the major factors contributing to this inertia has been the poor understanding of disease mechanisms. One way to elucidate these disease mechanisms is to study the association between the cardinal manifestations of glomerular diseases. Because many of these patients develop nephrotic syndrome, understanding the relationship of proteinuria, the primary driver in this syndrome, with hypoalbuminemia, hypercholesterolemia, hypertriglyceridemia, edema, and lipiduria could provide valuable insight. The recent unraveling of the relationship between proteinuria and hypertriglyceridemia mediated by free fatty acids, albumin, and the secreted glycoprotein angiopoietin-like 4 (Angptl4) offers a unique opportunity to develop novel therapeutics for glomerular diseases. In this review, the therapeutic potential of mutant forms of Angptl4 in reducing proteinuria and, as a consequence, alleviating the other manifestations of nephrotic syndrome is discussed.
authors.affiliation: Glomerular Disease Therapeutics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Lionel C
authors.initials: LC
authors.lastname: Clement
authors.affiliation: Glomerular Disease Therapeutics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Camille
authors.initials: C
authors.lastname: Macé
authors.affiliation: Glomerular Disease Therapeutics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Maria
authors.initials: M
authors.lastname: Del Nogal Avila
authors.affiliation: Glomerular Disease Therapeutics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama.
authors.forename: Caroline B
authors.initials: CB
authors.lastname: Marshall
authors.affiliation: Glomerular Disease Therapeutics Laboratory, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: chugh@uab.edu.
authors.forename: Sumant S
authors.initials: SS
authors.lastname: Chugh
mesh_terms: D000075803:Angiopoietin-Like Protein 4; D042682:Angiopoietins / Q000235:genetics / Q000494:pharmacology; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications*; D009404:Nephrotic Syndrome / Q000188:drug therapy* / Q000209:etiology; D011507:Proteinuria / Q000150:complications*; D011994:Recombinant Proteins
chemical_list: C474772:ANGPTL4 protein, human; D000075803:Angiopoietin-Like Protein 4; D042682:Angiopoietins; D011994:Recombinant Proteins